Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
LONG ACTING PAIN MANAGEMENT DRUG
 

Long-acting pain drug data positive: Pain Therapeutics

Study results of long-acting oxycodone showed positive data in osteoartritic patients with chronic pain.

 

BY OUR PHARMA CORRESPONDENT

13 September,2005: In the phase 3 study, the safety and efficacy of abuse-resistant oxycodone (Remoxy) was compared against placebo in osteoarthritic patients with moderate-to-severe chronic pain. The study design was randomized, double-blinded and enrolled 209 patients in over 20 U.S. clinical sites. Patients were treated with Remoxy 20 mg or matching placebo twice daily over a 4-week study period. Patient demographics and baseline pain scores were similar in both arms, reported Pain Therapeutics, Inc.

The primary objective of this study was to evaluate pain relief. Results demonstrated a statistically significant difference (p<0.05) between Remoxy and placebo in the study's primary endpoint: percent decrease in pain scores from baseline to final study visit, measured with a standard Likert Pain Scale.

The secondary objective of this study was to evaluate patients' quality of life. Results demonstrated statistically significant differences (p<0.05) between Remoxy and placebo in each component of the WOMACTM Osteoarthritis Index, in physical function measured by a standard SF-12(R) Health Survey and in patients' self-reported Quality of Analgesia.

The report mentioned no drug-related safety issues. However, it maintained that, as expected, opioid-related adverse events were higher in the Remoxy arm compared to the placebo arm. Adverse events typically associated with chronic opioid use include nausea/vomiting, dizziness, pruritus (itching), and somnolence/sedation. Also as expected, the patient drop-out rate was higher in the Remoxy arm (35%) compared to the placebo arm (24%). Patients in the Remoxy arm dropped mainly due to opioid-related adverse events. Patients in the placebo arm dropped mainly due to lack of efficacy.

The company plans to conduct a large, pivotal phase III registration study that can support a New Drug Application under an FDA filing strategy known as 505(b)(2). The company expects to initiate this study by year-end 2005.

Oxycodone is a strong opioid painkiller and is the active drug ingredient in Remoxy. Oxycodone is also the active drug ingredient in Oxycontin, a brand name drug with sales of nearly $2 billion in 2004. Long-acting versions of oxycodone are widely used to treat moderate-to-severe chronic pain. However, drug abusers can easily extract oxycodone from Oxycontin tablets (and all other marketed versions of long-acting oxycodone) in order to induce a quick and powerful euphoric high. Abusers of long-acting oxycodone risk respiratory depression, which can be fatal, and opioid addiction. According to government data, oxycodone abuse resulted in over 20,000 visits to emergency rooms and hundreds of deaths in 2002.

The FDA has not yet evaluated the merits, safety or efficacy of Remoxy. Remoxy has a sticky, high-viscosity mass that resists injection or snorting. Published data show that freezing, crushing or submerging Remoxy in high-proof alcohol for hours at a time releases just a fraction of oxycodone compared to Oxycontin at time points when abusers presumably expect to get high, a Pain Therapeutics release said. 

Pain Therapeutics Inc is a biopharmaceutical company. It develops candidates for severe chronic pain, such as low-back pain or pain due to osteoarthritis or irritable bowel syndrome. The company has three drug candidates in phase 3 clinical development: Oxytrex, Remoxy and PTI-901.

BY OUR PHARMA CORRESPONDENT

 

   Pharma Home
LATEST UPDATES

Chinese herbal products could be dangerous: UK 

Knock, knock! It's bird flu at the door

Spider anti-venom to be stocked in UAE hospital 

US may ban animal protein in cattle feed to safeguard against mad cow 

Dr Reddy's nizatidine generic gets FDA nod

Late-onset Pompe disease drug goes on trial

First biologic to treat ulcerative colitis gets US FDA okay

Diverticulitis orally dissolving pill from KV Pharma's  hits the market

Impax delisted from Nasdaq

US FDA okays Lupin's cephalexin

Hepatitis C combo therapy to get priority review in Japan

Lung cancer vaccine trials promising: Introgen

Sugar-free pill Actiq for cancer pain

39 drug firms sued over price rigging in California

Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us